منتجاتنا

Supply:

Maxima ^® 20 Capsule (140’s)        : Each box contains 10×14 capsules in Alu-Alu blister.

Maxima ^® 20 Capsule (70’s)         : Each box contains 5×14 capsules in Alu-Alu blister.

Maxima ^® 40 Capsule (40’s)         : Each box contains 4×10 capsules in Alu-Alu blister.

Maxima ^® 20 Tablet (140’s)          : Each box contains 10×14 tablets in Alu-Alu blister.

Maxima ^® 20 Tablet (70’s)            : Each box contains 5×14 tablets in Alu-Alu blister.

Maxima ^® 40 Tablet (40’s)             : Each box contains 4×10 tablets in Alu-Alu blister.

Maxima ^® IV Injection                     : Each box contains 1 vial of lyophilized Esomeprazole 40 mg     and 1 ampule of 5 ml 0.9% Sodium Chloride injection in blister strip & a 5 ml sterile disposable syringe

Composition:

Maxima ^® 20 Capsule: Each enteric coated tablet contains Esomeprazole Magnesium Trihydrate BP equivalent to Esomeprazole 20 mg as enteric coated pellets.

Maxima ^® 40 Capsule: Each enteric coated tablet contains Esomeprazole Magnesium Trihydrate BP equivalent to Esomeprazole 40 mg enteric coated pellets.

Maxima ^® 20 Tablet: Each enteric coated tablet contains Esomeprazole Magnesium Trihydrate BP equivalent to Esomeprazole 20 mg.

Maxima ^® 40 Tablet: Each enteric coated tablet contains Esomeprazole Magnesium Trihydrate BP equivalent to Esomeprazole 40 mg.

Maxima ^® IV Injection: Each vial contains lyophilized powder of Esomeprazole Sodium INN equivalent to Esomeprazole 40 mg.

Indications

Maxima is indicated for healing of erosive esophagitis, maintenance of healing of erosive esophagitis, symptomatic treatment of Gastroesophageal Reflux Disease (GERD), risk of reduction of NSAID-associated gastric ulcer, Helicobacter pylori associated ulcer, Zollinger-Ellison syndrome and other hyper acidic complications.

Dosage and Administration

Adults: Gastroesophageal Reflux Disease, Healing of Erosive Esophagitis: 20 or 40 mg once daily for 4-8 weeks, followed by a further 4-8 weeks if not fully healed. Maintenance of Healing of Erosive Esophagitis: 20 mg once daily. Symptomatic Treatment of Gastroesophageal Reflux Disease: 20 mg once daily for 4 weeks. An additional 4 weeks of treatment may be considered if symptoms do not resolve completely. Risk Reduction of NSAID-Associated Gastric Ulcer:  20 mg or 40 mg once daily for up to 6 months. Helicobacter pylori Associated Ulcer: One MAXIMA® 20, Amoxicillin (Moxilin) 1 g & Clarithromycin (Claricin) 500 mg all twice daily for 10 days. Zollinger-Ellison Syndrome: 40 mg twice daily. Injection: Gastroesophageal Reflux Disease: 40 mg once daily; Symptomatic reflux disease without esophagitis, treatment of NSAID-associated gastric ulcer and prevention of NSAID-associated gastric or duodenal ulcer: 20 mg dialy. Children: 1-11 years: 10 to 20 mg once daily. 12-17 years: 20-40 mg once daily. Injection:  No data available for the children. Impaired renal function: Dose adjustment is not required in patients with impaired renal function. Impaired hepatic function: Dose adjustment is not required in patients with mild to moderate liver impairment. For patients with severe liver impairment, a maximum daily dose of 20 mg should not be exceeded. Elderly: Dose adjustment is not required in the elderly patient.

OR AS DIRECTED BY THE PHYSICIAN.